{
    "clinical_study": {
        "@rank": "13327", 
        "arm_group": [
            {
                "arm_group_label": "ChloraPrep CHG/IPA Hi-Lite Orange Tint", 
                "arm_group_type": "Active Comparator", 
                "description": "Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%"
            }, 
            {
                "arm_group_label": "Normal Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% normal saline with applicator"
            }, 
            {
                "arm_group_label": "3M CHG/IPA Tint 10.5mL", 
                "arm_group_type": "Experimental", 
                "description": "Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL"
            }, 
            {
                "arm_group_label": "3M CHG/IPA Tint 26mL", 
                "arm_group_type": "Experimental", 
                "description": "Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% 26 mL"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the antimicrobial efficacy of the 3M CHG/IPA Prep\n      on skin flora of the abdomen and inguinal regions of human subjects."
        }, 
        "brief_title": "In-vivo Efficacy Study of Patient Pre-operative Preps", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Bacterial Reduction on Skin Flora Post-product Application", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects of any race\n\n          -  Subjects in good general health\n\n          -  Minimum skin flora baseline requirements on abdomen and groin\n\n        Exclusion Criteria:\n\n          -  Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin\n             disorders (including acne) on the applicable test areas\n\n          -  Topical antimicrobial exposure within 14 days prior to screening and treatment days\n\n          -  Use of systemic or topical antibiotics, steroid medications, or any other products\n             known to affect the normal microbial flora of the skin within 14 days prior to\n             screening and treatment days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "330", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968707", 
            "org_study_id": "EM-012760"
        }, 
        "intervention": {
            "arm_group_label": [
                "ChloraPrep CHG/IPA Hi-Lite Orange Tint", 
                "Normal Saline", 
                "3M CHG/IPA Tint 10.5mL", 
                "3M CHG/IPA Tint 26mL"
            ], 
            "intervention_name": "CHG 2% / IPA 70%", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "surgical prep", 
            "CHG", 
            "IPA"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "contact": {
                "last_name": "Muhammad H Bashir, MD, CCRP", 
                "phone": "703-925-0100"
            }, 
            "facility": {
                "address": {
                    "city": "Sterling", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "20164"
                }, 
                "name": "Microbiotest"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions", 
        "overall_contact": {
            "last_name": "Muhammad H Bashir, MD, CCRP", 
            "phone": "703-925-0100"
        }, 
        "overall_official": {
            "affiliation": "MICROBIOTEST", 
            "last_name": "Muhammad H Bashir, MD, CCRP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "A 2-log per cm2 bacterial reduction on the abdomen and a 3-log per cm2 bacterial reduction on the inguinal region.", 
                "safety_issue": "No", 
                "time_frame": "10 minutes post-product application"
            }, 
            {
                "measure": "Skin flora does not return to baseline on the abdomen and inguinal region.", 
                "safety_issue": "No", 
                "time_frame": "6 hours post-product application"
            }, 
            {
                "measure": "Safety as assessed by Skin Irritation score and Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "10 minute to 6 hour post-product application"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968707"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "3M", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "3M", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}